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Abstract
The glutamate hypothesis is a new theory of schizophrenia which proposes that
deficient glutamatergic transmission at the NMDA receptor underlies the positive,
negative, and cognitive symptoms of the disorder. In addition to tracing the development
of the glutamate hypothesis in depth, this senior project presents a study investigating the
effects of a novel antipsychotic in zebrafish. Zebrafish are an emerging model of several
CNS disorders, including schizophrenia, and it has been demonstrated that NMDA-R
antagonism induces motor hyperactivity in zebrafish adults and larvae. Previous research
supports an ability of typical and atypical antipsychotics to reverse these motor effects in
zebrafish adults. The present study investigates the motor effects of MK-801
administration in TL zebrafish larvae (n = 208) at two dose levels, as well as the ability of
CHPG (an agonist at the metabotropic glutamate 5 receptor) to reverse these effects. The
findings indicate that MK-801 decreased motor activity at a dose of 20 µM. CHPG
increased motor activity at a dose of 360 µM, an effect that was blocked by coadministration of 2 µM MK-801. The relevance of these findings to the development of
antipsychotics based on the glutamate hypothesis is discussed.
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Introduction
This senior project will focus on a new hypothesis of schizophrenia called the
glutamate hypothesis. The glutamate hypothesis postulates that disruption of
glutamatergic transmission at NMDA receptor sites underlies the positive, negative, and
cognitive symptoms of schizophrenia. Since the 1950s, neurological hypotheses of
schizophrenia have focused their attention on dopaminergic systems in the brain. The
glutamatergic systems that are the focus of the glutamate hypothesis have a
“downstream" effect on these dopaminergic systems, allowing the old ways of thinking to
be incorporated into the new, and painting a compelling new picture of the neural
mechanisms underlying schizophrenia symptomatology. Animal models play an
important role in development of glutamate based antipsychotic agents, and in this
project a larval zebrafish model is used to investigate the effects of CHPG, a positive
modulator of the metabotropic glutamate receptor type 5. The findings of this research
are discussed into the context of the literature surrounding novel pharmacotherapies for
schizophrenia.
The first chapter will introduce the reader to schizophrenia. Following a brief
examination of the psychological, social, and economic burdens of the disease, the three
main categories of symptoms (positive, negative, cognitive) will be introduced and
examples will be provided for each.
The second chapter will describe how the dopamine hypothesis has attempted to
account for schizophrenic symptoms. Starting with the first use of a dopamine antagonist
for antipsychotic treatment, the origins of the dopamine hypothesis will be explained
alongside early evidence for the involvement of dopaminergic transmission in
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schizophrenia. The chapter will explain the mechanisms of action of D2 antagonists and
clozapine (an atypical antipsychotic), and will list the side effects of these drugs which
have contributed in part to the continual development of novel antipsychotic agents.
Perhaps most importantly, the chapter will summarize the dopamine hypothesis’
theoretical gaps surrounding the negative and cognitive symptoms, as well as the unmet
therapeutic needs left by the typical and atypical antipsychotics.
The third chapter will begin with a history of the glutamate hypothesis, which
stems from the findings of neurological studies on dissociative anaesthetics such as PCP
and ketamine, drugs that block the NMDA glutamate receptor. This will lead into a
description of the proposed model of glutamate disruptions in pathways that act on the
dopamine pathways described in the previous chapter. The chapter will end with an
overview of the metabotropic glutamate receptors, with a specific focus on the
metabotropic glutamate type 5 receptor and agents that modulate activity at this receptor.
The fourth chapter will review recent studies on zebrafish that support the
glutamate hypothesis. The findings of these studies will in part provide a rationale for the
study conducted in this senior project. The main component of this chapter is an
empirical study testing the effects two different dose levels of MK-801, a non-selective
NMDA receptor antagonist, and CHPG, an agonist at the metabotropic glutamate
receptor type 5, on motor activity in larval zebrafish whether administered individually or
together.
The final chapter will summarize the findings of the zebrafish study in the context
of the glutamate hypothesis and will conclude with suggestions for future research.
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Chapter I: Schizophrenia and its Symptoms
Schizophrenia is the most prevalent and best known, as well as the most persistent
and debilitating, of all the psychotic disorders. It is a chronic illness that ranks among the
top ten causes of disability in developing countries (WHO 2002). The world wide
prevalence of schizophrenia has been reported at 1-1.1%. In the United States, there are
over 300,000 acute schizophrenic episodes annually. It is an illness that causes great
psychological and emotional suffering to those who have it. Rates of depression and
social isolation are high among those with schizophrenia. The mortality rate of people
with schizophrenia is eight times as high as that of the general population, due in part to
the fact that between 25-50% of people with schizophrenia will attempt suicide. Recent
meta-analyses have concluded that 4-4.9% of schizophrenics commit suicide (Palmer et.
al. 2005; Inskip et. al. 1998), compared to a 2-9% suicide rate among people with
depression (Mayo Clinic 2000). The World Health Organization reports an average
reduced life expectancy of 10 years (Samnaliev & Clark 2008). The illness also
represents a great burden to society as a whole, with 15% of people with schizophrenia
residing for long periods in state or county mental health facilities (Javitt & Coyle 2004).
Patients with schizophrenia occupy about 25-30% of all beds in hospitals, as well as
accounting for 40% of all long term care days in the U.S (Chavez-Noriega et. al. 2002).
According to Javett and Coyle (2004) around 15% of people with schizophrenia end up
incarcerated for petty crimes and vagrancy, 60% live in poverty, and 5% are homeless.
The estimated annual costs for treatment are $20-35 billion in the U.S. alone, an amount
that jumps to over $46 billion when the cost of lost productivity is factored in. These
statistics hint at the importance of finding effective ways to manage symptoms and care
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for people with this disease. Although a pharmacological approach is the most widely
accepted and effective form of treatment for both acute and chronic schizophrenia,
antipsychotics alleviate all symptoms in only about 20% of patients (Javitt & Coyle
2004), while 30% of patients are completely unresponsive to typical antipsychotic
treatment (Chavez-Noriega et. al. 2002). Furthermore, even among those who do
respond to treatment with antipsychotic drugs, a large number discontinue their
medication due to the unpleasant side effects.
According to the DSM-IV-TR: “The essential features of Schizophrenia are a
mixture of characteristic signs and symptoms (both positive and negative) that have been
present for a significant portion of time during a 1-month period (or for a shorter time if
successfully treated), with some signs of the disorder persisting for at least 6 months”
(American Psychiatric Association, 2000, p. 298). The terms “positive” and “negative”
respectively refer to whether a particular symptom is problematic because of the presence
of a maladaptive behavior or cognitive pattern, or because of the absence of a usually
adaptive behavior or pattern of cognition. Positive symptoms represent distortions and
exaggerations of normal cognitive functions, and negative symptoms represent a
diminution or loss of normal functions. According to the DSM-IV-TR, positive
symptoms include distortions in thought (delusions), distortions in perception
(hallucination), disorganized language and speech, and disorganized self-monitoring
behavior; negative symptoms include affective flattening, alogia (poverty of speech),
anhedonia (lack of pleasure), and avolition. In addition to the positive and negative
symptoms, people with schizophrenia also suffer from cognitive symptoms, which can
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include impaired attention, impaired informational processing, problems with serial
learning, and problems with executive functioning (Stahl 2002).
Positive symptoms are further divided into two dimensions: psychotic and
disorganized. Psychotic symptoms include delusions and hallucinations while
disorganized symptoms includes abnormalities in the form and structure of thought,
speech, and behavior.
Delusional beliefs have four key features: they are objectively false, idiosyncratic,
illogical, and stubbornly maintained. Delusions of influence consist of the patient
believing they are being controlled by an outside force (delusions of control), that alien
thoughts have been “inserted” into their mind against their will (thought insertion), or that
an outside force has taken away their thoughts (thought withdrawal). Delusions of selfsignificance consist of gross distortions of self-importance, the belief that environmental
sources are continually referencing the patient, or the assumption of illogical and
exaggerated guilt or responsibility.
The hallucinations present in schizophrenia are most often auditory (80%),
although they can be visual, olfactory, gustatory, or tactile (Stahl 2002). These
hallucinations are distortions or disruptions of normal perceptual functioning, and can be
very distressing for the schizophrenic person. The most common hallucinations are
auditory hallucinations in the form of spoken voices. A particularly problematic subtype
of auditory hallucinations is called “command hallucinations”, in which voices tell an
individual to hurt his/herself or others (Javitt & Coyle 2004).
While hallucinations and delusions represent the psychotic dimension of positive
symptoms, the speech/thought disorder in schizophrenia, as well as agitation, represents
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the disorganized dimension. This symptom dimension is expressed as exaggerations or
distortions in speech and thought. In diagnostic interviews, people with schizophrenia
may give answers that are irrelevant or incoherent, and have trouble maintaining a
logical, cohesive flow to their speech; they may jump from one subject to another with no
transitions, or speak in loose associations; they may use neologisms (newly created words
or idioms that do not make any sense); or they may repeat certain words and phrases over
and over (Stahl 2002). Agitation, another symptom of the disorganized dimension, may
be expressed as stereotyped behavior or diminished impulse control, and can also be
expressed in speech as “word salad” (Javitt & Coyle 2004). Additionally, motor
symptoms appear in at least 50% of psychotic patients (Seibt et. al. 2010).
The negative symptoms of schizophrenia are characterized by a reduction in
normal functioning. Affective flattening or “blunted affect”, a commonly observed
negative symptom, consists of restrictions in the range and intensity of the person’s
emotional expression, and is; alogia is a restriction in the fluency and productivity of
thought and speech; avolition is a restriction in the initiation of goal-directed behavior,
speech, or movement; anhedonia is a restriction in the ability to feel pleasure (Stahl
2002). Another negative symptom is “autism” (not to be confused with the disorder on
the autism spectrum), which refers to a loss of interest in other people or a one’s own
surroundings (Javitt & Coyle 2002).
Individuals with schizophrenia also display cognitive symptoms, deficits or
disruptions in normal cognitive functioning. While individuals with schizophrenia are
likely to exhibit impairment on a wide assortment of neuropsychological tasks, recent
findings have specifically highlighted deficits in selective attention, executive function,
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motor and tactile dexterity, special abilities, affect recognition, intellectual ability,
language functions, and memory (Heinrichs & Zakzanis 1998). For instance, a
characteristic cognitive symptom of schizophrenia is prepulse inhibition (PPI)
impairment. PPI is the ability to adapt to an loud auditory stimulus that is preceded by a
warning tone. People with schizophrenia have been found to have deficiencies in their
PPI. It is believed to reflect a defect in attentional “filtering” of nonnovel stimuli (Goff
& Coyle 2001). Additionally, individuals with schizophrenia tend to show impairment
on tasks that test working memory, such as spatial delayed-response tasks, the Wisconsin
Card Sorting Task, the Stroop test, and the Tower of London task (Goldman-Rakic 1994).
The severity of an individual’s cognitive symptoms has been shown to be the best
predictor of long-term outcome (Chavez-Noriega 2002). This could be because the
severity of cognitive symptoms may represent the severity of the individual’s illness as a
whole, or because cognitive symptoms have functional consequences that affect longterm outcome. For instance, a literature review conducted by Green (1996) found that
performance on secondary verbal memory (the ability to recall lists of words or stories
after a time delay) and card sorting cognitive tasks predicted community functioning
outcome in people with schizophrenia; secondary verbal memory and vigilance (the
ability to discriminate targets from non-targets in cognitive response tasks) predicted
social problem-solving ability; immediate verbal memory (the ability to repeat back a
series of digits), secondary verbal memory, and vigilance predicted capacity for skill
acquisition in psychosocial rehabilitation programs. A recent longitudinal study by
Shrivasatva et. al. (2011) showed that regardless of improvement on the Clinical Global
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Rating scale, individuals with schizophrenia still displayed deterioration of visuo-motor
integration, working memory, and executive functioning over a period of ten years.
There is no question that if cognitive deficits are present, an individual can be
expected to experience difficulties in other areas of their life such as social and emotional
functioning. However, despite the evidence that cognitive symptoms are a severely
debilitating dimension of schizophrenia, current pharmacological treatments mostly offer
relief from only the positive symptoms of the disease, with minimal or no effect on the
negative and cognitive symptoms (Lindsley et. al. 2006). Therefore, relief from negative
and cognitive symptoms represents a substantial unmet medical need.
Sine the 1950s, the gold standard for treatment of schizophrenia has been
treatment with dopamine antagonists, which are generally efficacious for ameliorating
positive symptoms while ineffective for treating negative and cognitive symptoms. First
generation antipsychotics still represent a large percentage of the agents used, though
recently atypical antipsychotic treatment and development has become more prominent.
Atypical antipsychotics are compounds that have antagonist activity at serotonin (5HT)
type 2A receptors in addition to antagonist activity at dopamine type 2 receptors. They
have been shown to have less side effects than first generation antipsychotics – as well as
encouraging (albeit inconsistent) efficacy for a broader variety of symptoms than first
generation antipsychotics – but there is a lack of comprehensive understanding of why
they work when they do.
While researchers have continued to attempt to illuminate the mechanisms of
action of the atypicals antipsychotics, new psychotomimetic paradigms and the ongoing
need to find therapeutic agents with efficacy for both negative and cognitive symptoms
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has shifted the focus of much schizophrenia research onto the glutamate systems.
Glutamate-based drug therapies may be a novel way to treat negative and cognitive
symptoms alongside positive symptoms. In order to understand how this new class of
drug will work to affect changes in the brain and differ from first and second generation
antipsychotics, it is important to review the current theories of schizophrenia. The next
chapter will briefly explain the theoretical underpinnings that have historically guided
antipsychotic drug development, known as the dopamine hypothesis, as well as the
mechanisms by which antipsychotic drugs work.
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Chapter II: The Dopamine Hypothesis and Antipsychotics
For the last 60 years, pharmacotherapies and neurological models of
schizophrenia have focused heavily on one neurotransmitter: dopamine. Dopamine is a
member of the catecholamine family and plays an important role in behavior and
cognition, voluntary movement, punishment and reward, inhibition of prolaction
production, sleep, mood, attention, working memory, and learning. The dopamine
hypothesis states that dopamine dysregulation in the central nervous system results in the
symptoms of schizophrenia. The origins of this theory lie in the history of the
development of antipsychotic drugs. In 1950 a Naval surgeon named Henry Laborit
noted that the secondary effects of promethazine, a drug intended for use as a surgical
sedative, included drowsiness, indifference to pain, and general euphoria. Laborit began
to consider other possible applications for the drug, while also encouraging Laboratoires
Rhône-Poulenc to synthesize a similar compound with increased psychological effects.
Paul Charpentier was the chemist who then designed chlorpromazine (Thorazine) in
1951, which was distributed to physicians and psychiatrists for use as an antipsychotic.
By 1954 chlorpromazine was being used in the United States to treat schizophrenia, and
as its therapeutic use grew more popular, research was targeted at discovering its
neurological mechanism(s) of action.
By the early 1960s, empirical findings had shown that the first generation of
antipsychotics (commonly referred to as typical antipsychotics or neuroleptics) acted as
antagonists on dopamine type D2 receptors, binding to these receptor sites and decreasing
dopamine release. Furthermore, side effects resembling Parkonson’s disease were
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observed early on in clinical trials of antipsychotics, and these observations contributed
to the understanding that typical antipsychotics acted on dopamine neurons. Research
had already established Parkinson’s disease as a result of deficient dopamine in the brain,
especially in the nigrostriatal dopamine pathway (Mueser & Jeste 2008; Lauelle et. al.
2005; Stahl 2002). Around the same time, Arvid Carlsson demonstrated that
amphetamines administered to healthy subjects induce hallucinations and delusions
(analogous to the positive symptoms of schizophrenia) via indirect agonist activity at
dopamine D2 receptors. Carlsson’s research was inspired by earlier findings from studies
of symptoms present in patients hospitalized for amphetamine psychosis: the patients
frequently experienced auditory hallucinations much like those typically reported in
schizophrenia – vague noises, voices that the patients occasionally conversed with – as
well as visual hallucinations that resembled those reported by schizophrenic individuals
during acute psychotic episodes (Snyder et. al. 1974). The dopamine hypothesis arose out
of all of these early clinical observations. The current rationale for this hypothesis
implicates dopamine as a causative neurotransmitter in schizophrenia based on the
combined evidence that: 1) all clinically relevant antipsychotic agents display significant
antagonistic activity at the dopamine D2 receptor; 2) indirect dopamine agonists, such as
amphetamine and cocaine, have been shown to induce positive psychotic symptoms both
human and animal subjects; and 3) many of the patients treated with first generation
antipsychotics displayed Parkinsonian side effects, pointing towards dopamine
antagonism as the mechanism of action by which these drugs acted on the brain.
Informed by pharmacological discoveries, the dopamine hypothesis implicates
hyperactivity of dopamine in the mesolimbic dopamine pathway as the cause of the
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positive symptoms of the disease. The dopamine neurons of this pathway have cell
bodies located in the ventral tegmental area; dopamine is carried to the nucleus
accumbens via the amygdala and hypothalamus. Hyperactivity of dopamine neurons in
this pathway is thought to be responsible for the hallucinations and delusions present in
schizophrenia (Stahl 2003).
Figure 1. Dopamine hyperactivity in mesolimbic pathway results in overactive postsynaptic dopamine neurons.

Negative and cognitive symptoms are accounted for via a different dopamine
pathway. The mesocortical dopamine pathway is comprised of dopamine neurons whose
cell bodies are, like those of the mesolimbic pathway, located in the ventral tegmental
area. However, unlike those neurons of the mesolimbic pathway, these neurons project
dopamine to areas of the cerebral cortex, such as the dorsolateral prefrontal cortex, as
well as many structures in the limbic system (Stahl 2002). According to the dopamine
hypothesis, hypoactivity of these neurons is responsible for the negative and cognitive
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symptoms seen in schizophrenia. While there has been considerable progress in the
development of pharmacological agents to treat positive symptoms, biological treatments
for the negative and cognitive symptoms remain unsatisfactory.
All first generation antipsychotics (also known as typical antipsychotics, or
neuroleptics) inhibit dopamine 2 receptors. This ability to block D2 receptors is
responsible for their clinical efficacy. By inhibiting D2 receptors in the mesolimbic
dopamine pathway, neuroleptics can reduce hallucinations and delusions in people with
schizophrenia (Stahl 2002). The efficacy of a neuroleptic in reducing positive symptoms
is correlated with the compound’s affinity for the D2 receptor (Snyder et. al. 1974; Stahl
2002).

Figure 2. D2 Antagonists inhibit post-synaptic hyperactivity of dopamine neurons.
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While this method of drug treatment does provide reliable relief from positive
symptoms in a majority of patients (roughly 70%), there are several drawbacks to
neuroleptic treatment (Chavez-Noriega et. al. 2002). Antipsychotic drugs are delivered to
the brain through oral ingestion, and therefore these compounds bind non-selectively to
every D2 receptor in the brain, leading to decreased activity in both the mesolimbic
pathway and mesocortical pathway. The result is that, while positive symptoms are
alleviated due to antagonist activity in the mesolimbic pathway, negative and cognitive
symptoms may be worsened due to antagonism in the mesocortical pathway – a condition
referred to as the neuroleptic-induced deficit syndrome (Stahl 2002). Furthermore, many
side effects are a result of the fact that in addition to the two pathways already mentioned,
two other relevant dopamine pathways in the brain are blocked by neuroleptics – the
nigrostriatal dopamine pathway, and the tuberoinfundibular dopamine pathway.
The nigrostriatal pathway is part of the extrapyramidal nervous system,
responsible for controlling motor movements. In Parkinson’s disease, deterioration of the
nigrostriatal pathway is responsible for symptoms such as rigidity, akinesia (loss of
control of voluntary movement), bradykinesia (impaired ability to adjust one’s body
position), and tremor. By blocking D2 receptors in this pathway, typical antipsychotics
may cause drug-induced parkinsonism, as well as akathisia (a syndrome characterized by
unpleasant “inner restlessness” that may manifest as an inability to sit still or remain
motionless) and dystonia (characterized by twisting movements and abnormal postures
due to sustained muscle contractions). Side effects on movement resulting from reduced
dopamine in the nigrostriatal pathway are commonly referred to as extrapyramidal side
effects, or EPS. Chronic blockade of D2 receptors in the nigrostriatal pathway may
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produce a hyperkinetic movement disorder called tardive dyskinesia, characterized by
constant chewing, tongue protrusions, facial grimacing, and jerky or choreiform limb
movements (Stahl 2002). Annual incidence of neuroleptic-induced tardive dyskinesia is
5% (Stahl 2002), and in many cases it is an irreversible condition.
In addition to the side effects caused by blockade of the nigrostriatal pathway,
patients may experience side effects caused by blockade of the tuberoinfundibular
pathway. When D2 neurons in this pathway are blocked plasma prolactin levels increase,
which may result in a condition called hyperprolactimea. This condition is associated
with breast secretions, irregular menstrual periods, and demineralization of bones in
women. Further side effects may include sexual dysfunction and weight gain due to
elevated prolactin levels (Stahl 2002).
Clearly there are many risks inherent in conventional antipsychotic treatment
despite the benefits of alleviated positive symptoms. Side effects are associated with
discontinuation of medical treatment by patients at a rate of 10% per month, resulting in a
50% relapse rate by 6 months after medication has been discontinued (Stahl 2002).
Furthermore, 30% of individuals with schizophrenia do not respond to typical
antipsychotics (Chavez-Noriega et. al. 2002; Sajatovic et. al. 2008). The development of
atypical antipsychotics was intended to remedy this situation. The goal in the
development of the atypicals has been to decrease the prevalence of unpleasant side
effects as well as increase clinical efficacy for more symptoms in a larger portion of the
patient population.

The improved efficacy and reduced extrapyramidal side effects of

treatment with clozapine, the prototype drug of the atypical class, has led to the
development of atypicals such as risperidone, olanzapine, quetiapine, ziprasidone,
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aripiprazole, and paliperidone. According to a European review (Seshamini 2002)
treatment with clozapine improves patient symptoms and quality of life, as well as
reduces the number of hospitalizations in individuals with schizophrenia. Clozapine has
antagonist activity at dopamine type 2 receptors much like haloperidol. Additionally,
clozapine blocks seretonin type 2A (5HT-2A) receptors. Serotonin and dopamine
interact in the nigrostriatal dopamine pathway of the brain, the pathway responsible for
the Parkinsonian side effects that can be caused by treatment with typical antipsychotics
such as haloperidol. In this pathway, serotonin acts as a brake by inhibiting dopamine
neurons. By blocking 5HT-2A receptors here, 5HT-2A antagonism can reverse the
dopamine type 2 antagonism resulting from blockade of dopamine receptors, leading to
fewer or no extrapyramidal symptoms than those that result from the dopamine
antagonism of typical antipsychotics (Stahl 2002).
However, while atypical antipsychotics are not associated with the extrapyramidal
side effects that characterize neuroleptic treatment, the atypicals have their own side
effect profile which can contribute to the problem of treatment discontinuation in the
same way that typical antipsychotic side effects have. When compared to haloperidol,
clozapine is associated more with hypersalivation, temperature increase, and drowsiness,
but fewer motor side effects and less dry mouth (Sajatovic et. al. 2008). Clozapine side
effects can include agranulocytosis (dangerous lowering of white blood cell count leading
to increased risk of infections), granulocytopenia (another lowering of white blood cell
count), sedation, seizures, fevers (100-103˚F), neuroleptic malignant syndrome (a lifethreatening neurological disorder characterized by muscle rigidity, fever, autonomic
instability, and delerium), development of obsessive-compulsive symptoms, tachycardia
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(potentially dangerous increase of resting heart rate), orthostatic hypotension (low blood
pressure), prolongation of QTc interval (which may lead to palpitations, fainting, or
sudden death), deep vein thrombosis (blood clotting in various limbs), myocarditis
(inflammation of the heart muscles with a 20% mortality rate), cardiomyopathy
(deterioration of heart muscles), sialorrhea (excessive drooling), urinary retention,
constipation, gastrointestinal obstruction, and enuresis (involuntary urination) (Sajatovic
et. al. 2008). In addition, McGurk et. al. (2005) suggested that the anticholinergic effects
of clozapine may be responsible for the worsening of spatial working memory in
individuals with schizophrenia. Furthermore, research has failed to find consistent
significant data supporting atypical drugs efficacy for cognitive and negative symptoms.
On a final note, clozapine use is limited to about 5% of patients in clinical settings due to
its adverse side effect profile, need for regular laboratory monitoring, and cost (Satajovic
et. al. 2008).
The dopamine hypothesis has laid the foundations for an understanding of the
neural mechanisms underlying many symptoms of schizophrenia, as well as leading to
the development of antipsychotic agents. However, there are still unanswered questions
about the neural mechanisms of negative and cognitive symptoms, and current
antipsychotic treatments have been inconsistent in ameliorating these symptoms.
Additionally, the adverse side effect profiles of antipsychotics demonstrate that the
current state of pharmacotherapies for schizophrenia is one that can be improved upon.
In recent years a new hypothesis of schizophrenia, the glutamate hypothesis, has led to
the possibility of the development of antipsychotic treatments which are efficacious for a
broader range of symptoms, and which may also avoid the side effects of current
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antipsychotic administration. The next chapter will review the glutamate hypothesis, as
well as antipsychotic agents that have been developed based on this new direction in
schizophrenia research.
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Chapter III: The NMDA-R Hypothesis of Schizophrenia
In the last twenty years, researchers investigating the etiology of schizophrenia
have shifted their focus from dopamine systems to “upstream” glutamate systems that
have modulating effects on the relevant dopamine pathways implicated in schizophrenia.
Glutamate is the primary excitatory neurotransmitter in the brain, which means it
activates many neurons. It is fairly ubiquitous (60% of neurons contain glutamate, and
almost all neurons have some type of glutamate receptor), and plays a role in prenatal and
childhood development, learning, and memory (Harvard Mental Health Letter 2009).
Glutamate also has a modulating effect on the dopamine pathways implicated in the
dopamine hypothesis. By looking at glutamate’s role in schizophrenia, researchers have
begun to formulate a model of the disease which incorporates the whole of the dopamine
hypothesis while also accounting for aspects of schizophrenia which the dopamine
hypothesis has been unable to explain.
The glutamate hypothesis comes out of research with the dissociative anesthetics
PCP and ketamine. According to Javitt & Coyle (2004) studies first drew parallels
between the effects of PCP and the symptoms of schizophrenia as early as the 1960s.
PCP acts as a nonselective antagonist at the NMDA glutamate receptor, binding to a site
within the ion channel and blocking the influx of cations that leads to an action potential
(Goff & Coyle 2001). The NMDA receptor is a ligand- and voltage-gated
calcium/sodium channel that is believed to play a role in both learning and memory
(Sison & Gerlai 2011; Javitt 1987), . Ketamine has the same mechanism of action at the
NMDA receptor, with a lower affinity than PCP. As psychotomimetics, there is

ASSESSMENT OF A NOVEL ANTIPSYCHOTIC IN ZEBRAFISH

24

compelling evidence that these NMDA receptor antagonists can produce a psychotic state
more closely resembling the symptom profile of schizophrenia than dopamine agonists
such as amphetamine or methylphenidate. While dopamine agonists only induce effects
similar to the positive symptoms of the disease, PCP and ketamine can give rise to a state
that resembles the full range of positive and negative symptoms in schizophrenia
including hallucinations, thought disorder, specific cognitive impairment, emotional
withdrawal, and apathy (Javitt 1987; Stone 2009). PCP can produce a syndrome in
normal individuals that closely resembles schizophrenia and exacerbates symptoms in
patients with chronic schizophrenia (Luby et. al. 1959). Ketamine can produce positive
symptoms in the form of suspiciousness, disorganization, and auditory and visual
hallucinations; negative symptoms in the form of blunted affect, withdrawal, and
psychomotor retardation; and cognitive symptoms including impaired performance on the
Wisconsin Card Sorting Test (which is used to test a number of cognitive abilities
including attention, memory, visual processing, and other executive functions) and on
verbal declarative memory, delayed word recall, and impairment on verbal fluency tests
(Goff & Coyle 2001). In fact, both ketamine and PCP mimic schizophrenia so well that
patients treated with either of these drugs cannot be readily distinguished from
individuals with schizophrenia in clinical settings (Javitt & Zukin 1991).
Observations on the psychomimetic effects of these NMDA receptor antagonists
have led to the development of a NMDA-R hypothesis of schizophrenia, referred to as
the glutamate hypothesis. The glutamate hypothesis attributes the symptoms of
schizophrenia to hypofunctional NMDA receptors that have a downstream effect on the
two major dopamine pathways implicated in the dopamine hypothesis. There is an
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important descending glutamatergic pathway which projects from cortical pyramidal
neurons to dopamine neurons in the ventral tegmental area (VTA), which normally acts
as a brake on the mesolimbic dopamine pathway by exciting γ-aminobutyric acid
(GABA) interneurons in the VTA to inhibit dopamine release from the mesolimbic
pathway. Hypoactivity at NMDA receptors in schizophrenia would lead to a decrease in
activation of GABA interneurons, thereby leading to hyperactivity of the mesolimbic
pathway – responsible for the positive symptoms of the disease (hallucinations,
delusions, thought disorder, agitation).
Figure 3. NMDAR hypofunction leads to positive symptoms (Stahl 2002).

QuickTime™ and a
decompressor
are needed to see this picture.

Another important glutamate pathway extends from the cortical regions of the brain
caudally to the brainstem, and the neurons of this pathway normally have an excitatory
effect on the dopamine neurons of the mesocortical dopamine pathway. Hypoactivity at
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NMDA receptors in schizophrenia would lead to decreased dopamine activity in the
mesocortical pathway – thereby accounting for the negative symptoms (blunted affect,
withdrawal, avolition) and cognitive symptoms (working memory impairment, executive
functioning deficits) of the disorder (Stahl 2007).
Figure 4. NMDAR hypofunction leads to negative and cognitive symptoms (Stahl
2002).

QuickTime™ and a
decompressor
are needed to see this picture.

Several neurological findings are consistent with the glutamate hypothesis:
studies have shown significantly lower levels of glutamate in the cerebrospinal fluid and
postmortem brain tissue of individuals with schizophrenia than in controls; cerebrospinal
fluid glutamate levels have been shown to be inversely correlated to the severity of
positive symptoms in unmedicated individuals with schizophrenia; levels of kyuneric
acid (an endogenous ionotropic glutamate antagonist with activity at the glycine site of
NMDA receptors) have been found to be elevated in the cerebrospinal fluid and cortical
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tissue of schizophrenics compared to controls; and a number of studies have reported
alterations in gene and receptor expression in cortical, hippocampal, and thalamic regions
for several glutamate receptors including the NMDA receptors (Chavez-Noriega et. al.
2002).
Genetic findings from animal models also support the glutamate hypothesis.
Several studies have shown that decreased expression of the NR1 subunit, required in
mice for normal NMDA receptor function, leads to a range of phenotypic symptoms
analogous to schizophrenia such as increased locomotor activity, stereotypy and deficits
in social and sexual interactions, which can be ameliorated by treatment with haloperidol
and clozapine (Chavez-Noriega et. al. 2002); furthermore, symptoms such as disruption
of pre-pulse inhibition, spatial working memory, and GABA interneuron expression are
more likely to occur if NR1 deletion occurs during early developmental windows –
consistent with the neuro-developmental aspect of schizophrenia (Gordon 2010). NR2
knockout display schizophrenic-like behaviors that can be ameliorated with antipsychotic
drug treatment, and NR1 glycine site knockout mice display impairment in LTP and
learning (Linsley et. al. 2006). A study using metabotropic glutamate type 5 receptor
knockout mice demonstrated a significant reduction in the NMDA-component of synaptic
transmission, as well as long-term potentiation, in hippocampal field CA1 and the dentate
gyrus (Lu et. al. 1997). Kinney et. al. (2003) were able to demonstrate that mGluR5
knockout mice had significant deficits in PPI when compared to wild-type controls.
In light of the growing body of evidence in support of the glutamate hypothesis, it
has been suggested that modulation of glutamatergic transmission be used as a novel
pharmacotherapy for schizophrenia, and thus several compounds that have action at
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glutamate receptors have been developed for research. Metabotropic glutamate receptors
(mGluRs) have emerged as promising targets for development of new ligands. The
relative uneven distribution in the brain of mGluRs, compared to ionotropic glutamate
receptors (iGluRs), gives rise to the possibility that selective modulators of mGluR
function might be used to target specific aspects of glutamatergic activity in specific
neural circuits. While none of these agents are currently approved for clinical use in
humans because they are still so early in the development and research process, several
studies have shown that modulation of glutamatergic transmission at metabotropic
receptor sites may be able to ameliorate symptoms of schizophrenia.
The metabotropic glutamate receptors belong to the family C of seven
transmembrane receptors that couple with G proteins and control to the activity of
membrane enzymes and ion channels in the neuron (Kanuma et. al. 2010). There are
eight known types of mGluRs classified into groups I, II, and III according to primary
structure, second messenger coupling, and pharmacological profile. Group I (containing
mGluR1 and mGluR5) and group II (containing mGluR2 and mGluR3) have both been
identified as potential targets for novel antipsychotic agents.
Figure 5. Classification of metabotropic glutamate receptors.
Group

Receptor

I
I

mGluR1
mGluR5

Signal
transduction
mechanism
⇑PLC
⇑PLC

Primary localization

Postsynaptic; forebrain/midbrain
Glia, postsynaptic;
forebrain/midbrain
II
mGluR2
Pre/postsynaptic; forebrain
⇓AC
II
mGluR3
Glia, postsynaptic; forebrain
⇓AC
III
mGluR4
Pre/postsynaptic; cerebellum
⇓AC
III
mGluR6
Postsynaptic; retina
⇓AC
III
mGluR7
Pre/postsynaptic
⇓AC
III
mGluR8
Pre/postsynaptic
⇓AC
AC = adenylate cyclase; PLC = phospholipase C; ⇑ indicates increase; ⇓ indicates decrease.
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Multiple studies have shown that activation of group I mGluRs induces
potentiation of NMDA receptor currents in a variety of regions in the brain (Sou et. al.
2006; Chan et. al. 2008). In particular, activation of mGluR5 has been shown to alleviate
locomotor, sensorigating, and cognitive deficits induced by NMDA receptor antagonists.
Chavez-Noriega et. al. (2002) have hypothesized that activation of mGluR5 may
normalize hypofunctional NMDAR transmission in schizophrenia, thereby representing a
useful approach for the development of novel antipsychotic drug treatments. There is
supporting evidence from studies on mGluR5 antagonists, which have demonstrated that
the mGluR5 antagonists MPEP and MTEP can worsen motor and cognitive symptoms
induced by NMDA receptor antagonists (Krystal et. al. 2010). According to Kanuma et.
al. (2010) the mechanism by which activation of mGluR5 with agonist agents enhances
NMDAR function is that it is likely that activation of mGluR5 leads to PKC
phosphorylation of the ion channel associated with NMDA receptors, thereby resulting in
increased NMDA receptor sensitivity and activity, and leading to an influx of calcium
ions. Figure 6, adapted from Kamuna et. al. (2010), is an illustration that shows this
chain of events: glutamate binds to the mGluR5 site (drawn as a 7-transmembrane
protein), triggering the activation of a second messenger (Gqu), leading to PKC
phosphorylation, resulting in enhanced ionic influx.
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Figure 6. mGluR5 activation enhances NMDAR function (Kanuma et. al. 2010)

One particular compound that has been shown to have antipsychotic effects in
rodent models of psychosis is the mGluR5 agonist (RS)-2-chloro-5hydroxyphenylglycine (CHPG). Sou et. al. (2006) administered CHPG via
introcerebralventricular (i.c.v.) injections to male NMRI mice that had been treated with
either ketamine or propofol (an anaesthetic which binds to GABA subtype A neurons).
Results indicated that CHPG decreased the duration of ketamine-induced loss of right
reflex (LORR) at 3 dose levels (0.5, 2.5, and 5.0 nmol in a 5µL injection) in a dose
dependant manner (5.0 nmol dose resulted in the shortest duration of LORR), but did not
have an affect on propofol-induced LORR. This supports the hypothesis that CHPG acts
via modulation of NMDA receptors.
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Figure 7. Structure of CHPG.

In another study, Chan et. al. (2008) examined whether CHPG could reverse
ketamine induced locomotor hyperactivity, motor incoordination, sensorimotor gating
deficit, and learning impairment in male NMRI mice (a Swiss-bred type) and ICR
(Inherited Cataract Rat, bred for research in neurobiology and opthamology) rats. CHPG
reversed ketamine-induced hyperactive locomotor activity at a dose of 5 nmol delivered
via a 5µL i.c.v. injection, but did not affect motor activity when delivered alone. CHPG
also improved ketamine-induced deficits in the novel object recognition test at doses of 1
nmol and 5 nmol, respectively. CHPG did not alter sensorimotor gating, motor
coordination on the rotarod test, or cognitive abilities in the novel object recognition test
when delivered alone. This study supports the hypothesis that CHPG may be binding
directly to the orthosteric (direct) glutamate binding site and thus increasing the intrinsic
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effect of endogenous glutamate, leading to the enhancement of NMDA receptor function;
at the same time, the fact that the drug had no effect on these measures when
administered alone opposes the possibility that the reversal of ketamine-induced
hyperactivity was due to a sedative effect, or that the reversal of cognitive deficits in the
novel object recognition test was due to anxiolytic effects.
Current investigations into the ability of mGluR5 agonism to alleviate the effects
of NMDA-R antagonism have been limited to rodent models of psychosis. Zebrafish
(Danio rerio) is an emerging animal model of the behavioral and cognitive disruptions
caused by NMDA-R antagonism. A small number of studies have demonstrated the
ability of first and second generation antipsychotic treatment to alleviate the behavioral
and brain changes induced by MK-801 (a non-selective NMDA-R antagonist), . Taken
together, these findings suggest a rationale for investigating whether or not mGluR5
agonism can reverse the behavioral disruptions caused by administration of MK-801.
The next chapter will include the rationale, methods, results, and discussion of a pilot
study conducted to investigate the effects of CHPG on MK-801-induced motor symptoms
in zebrafish larvae.
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Chapter IV: Assessing CHPG Reversal of Locomotor Effects of MK-801 in
Zebrafish Larvae
Background
Schizophrenia is a central nervous system disorder characterized by positive,
negative, and cognitive symptoms. All currently approved antipsychotic drugs share the
trait of reducing dopaminergic function via antagonist or partial antagonist activity at
dopamine type 2 receptors. One consequence of this is that most antipsychotics are only
effective for the treatment of the positive symptoms of the disorder (hypothesized to be a
result of dopaminergic hyperactivity in the mesolimbic dopamine pathway), while
negative and cognitive symptoms (hypothesized to be a result of dopaminergic
hypoactivity in the mesocortical dopamine pathway) are alleviated inconsistently, if at
all. Thus, there is an incentive to develop pharmacotherapies that will be efficacious for
the whole range of symptoms present in schizophrenia. In the last 10 years, research has
begun to explore modulation of glutamatergic systems as a novel approach to
antipsychotic treatment.
The dopamine pathways implicated in schizophrenia are “downstream” from key
glutamate systems in the brain. Hypoactivity of the glutamate systems that act on the
mesolimbic and mesocortical dopamine pathways has recently been implicated in the
etiology of schizophrenia. In particular, it has been suggested that dysfunction at the Nmethyl-D-aspartate (NMDA) glutamate receptor may play an important causal role in
mediating positive, negative, and cognitive symptoms. The NMDA receptor is a ligandand voltage-gated calcium/sodium cation channel that is believed to play a role in both
learning and memory (Sison & Gerlai 2011; Javitt 1987). Non-selective NMDA-R
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antagonists, such as PCP and ketamine, have been found to elicit symptoms in healthy
controls that resemble the variety of symptoms found in individuals with schizophrenia.
Importantly, the state induced by administration of NMDA-R antagonists more
accurately models the full range of symptoms in schizophrenia than the psychosis
induced by treatment with amphetamines, which increase dopaminergic activity and have
heretofore been the most popular method of eliciting schizophrenic-like symptoms (Javitt
1987; Stone 2009).
Animal models of psychosis provide opportunities for investigation into different
aspects of schizophrenia. The zebrafish (Danio rerio) is emerging as a model organism
for examining the interactions of toxicology, neurodevelopment, and behavior (Padilla et.
al. 2011). The small (4 cm long) freshwater teleost that inhabits slow moving streams
and small lakes of the Indian sub-continent has been argued to represent an excellent
compromise between neurological complexity and practical simplicity (Sison & Gerlai
2011). The many advantages to zebrafish include low cost, ease of handling and
maintenance, and 70-80% genetic homology to humans (Seibt et. al. 2011). Recent
findings suggest that zebrafish may be useful in modeling schizophrenic symptoms via
administration of NMDA-R antagonists.
Dizocilpine (MK-801) is a non-selective NMDA-R antagonist that has been used
in animal models of psychosis to elicit motor and cognitive effects. Treatment with MK801 has been demonstrated to lead to a dose-dependent increase in motor activity in both
rodent and adult and larval zebrafish models analogous to the positive symptom
dimension in schizophrenia. The motor effects of MK-801 are hypothesized to be
mediated by blockade of glutamatergic transmission leading to enhanced dopaminergic
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activity. This mechanism of action is consistent with the mechanism of positive
symptoms proposed by the NMDA-R hypofunction hypothesis of schizophrenia.
Swain et. al. (2004) used a zebrafish model to examine the effects of MK-801 on
circling behavior, swimming activity, latency to enter (as well as preference for) an
enriched chamber. Consistent with findings that treatment with PCP or other NMDA
receptor antagonists increase circling behavior in rodents, it was demonstrated that MK801 significantly increased circling behavior in adult zebrafish at a dose of 2 and 20 µM
in a dose-dependent manner. Treated fish circled “almost continuously”, whereas control
fish displayed motor activity but rarely completed a full 360 degree circle. Preference for
the enriched chamber was also disrupted in fish treated with MK-801 as compared to
controls, suggesting a possible cognitive disruption due to MK-801 treatment.
Seibt et. al. (2010) demonstrated that a dose of 20 µM MK-801 increased
locomotor activity in adult zebrafish as measured by parameter line crossings, distance
traveled, and mean speed when compared to control animals. Co-administration of either
9 µM haloperidol, 100 µM olanzipine, or 250 µM sulpiride was shown to reverse the
changes in locomotor behavior induced by MK-801. In another study, Seibt et. al. (2011)
demonstrated that treatment with 20µ MK-801 significantly decreased Na+, K+, ATPase
activity (which is altered in various neuropsychiatric illnesses including schizophrenia) in
adult zebrafish. This effect was reversed by administration of antipsychotics (haloperidol
9 µM, olanzipine 100 µM, or sulpiride 250 µM). Taken together, the findings of these
two studies provide a rationale for investigating whether a novel antipsychotic agent
could have the ability to reverse the effects of MK-801 in zebrafish.

ASSESSMENT OF A NOVEL ANTIPSYCHOTIC IN ZEBRAFISH

36

The previously cited findings are from studies on adult zebrafish, and to date there
are very few studies on larval models that exist in the current literature. However, in
light of the proposed neurodevelopmental aspect of schizophrenia there may be
knowledge to gain from investigations into zebrafish larvae as potential models of
schizophrenic symptoms and antipsychotic effects. A recent study provides support for
the conservation of the motor effects of MK-801 in zebrafish larvae. Chen et. al. (2010)
demonstrated a dose-dependent effect of MK-801 on locomotor activity in zebrafish
larvae 5-7 d.p.f.. MK-801 was found to significantly increase average swim speed over a
3 hour period when administered at doses of 5, 10, 20, 50, and 100 µM. The dose that
elicited the maximal increase in average swim speed was 20 µM. This study provides
evidence that the hyperactive motor effects of MK-801 previously demonstrated in adult
zebrafish are conserved in zebrafish larvae, contributing to a rationale for investigating
the effects of potential antipsychotics in larval models. The dose effects from the study
also contribute to the rationale for using a 20 µM dose of MK-801 in the present study.
(RS)-2-chloro-5-hydroxyphenylglycine (CHPG) is a novel glutamate-based
compound which selectively binds to the metabotropic glutamate type 5 receptor
(mGluR5). It has previously been shown to have antipsychotic activity in rodents.
CHPG is hypothesized to modulate glutamatergic transmission via enhancement of
NMDA-R function. According to Alioto & Ngai (2006) zebrafish have a genetic
ortholog that codes for an mGlu5 receptor. While previous studies have examined the
effects of NMDA-R antagonism in zebrafish, to date the ability of glutamate based
compounds to enhance NMDA-R function have never been investigated in zebrafish.
Furthermore, despite the fact that a number of studies have demonstrated that mGluR-
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binding ligands have behavioral effects in rodents, there are very few studies that have
assessed the degree to which these findings can be replicated in a zebrafish model.
However, the ability of the mGluR5 antagonist MPEP (an mGluR5 antagonist which has
been shown to increase the effects of NMDA-R antagonists) to affect the behavior of
zebrafish in an addiction model (Tucker et. al. 2006) is sufficient reason to investigate
whether an mGluR5 agonist can also affect larval behavior.

Experiment 1
The purpose of this study was to assess whether treatment with the mGluR5
agonist CHPG has any independent effects on motor activity in zebrafish larvae, as well
as whether treatment with CHPG can reverse the locomotor hyperactivity MK-801 has
previously been demonstrated to induce in zebrafish. In order to achieve this, zebrafish
larvae were observed at 5 days post fertilization following treatment with either vehicle
(egg water), MK-801, CHPG, or a mixture of MK-801 and CHPG. The previously cited
studies by Swain et. al. (2004), Chen et. al. (2010), and Seibt et. al. (2011) provide
compelling evidence to hypothesize that the zebrafish treated with MK-801 would exhibit
increased motor activity from baseline as compared to controls. Additionally, it was
hypothesized that the motor activity of zebrafish treated with CHPG alone would not
differ significantly from controls. The rationale for this prediction was based on findings
of Kinney et. al. (2003) and Chan et. al. (2008) which demonstrated that while CHPG
was able to reverse NMDA-R antagonist-induced motor and cognitive symptoms in
rodents, there was no effect on these measures when administered alone,. This is
consistent with the hypothesis that CHPG may be binding directly to the orthosteric
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glutamate binding site and increasing the intrinsic effect of endogenous glutamate,
leading to the enhancement of NMDA receptor function. It was also hypothesized that
fish treated with both MK-801 and CHPG would exhibit significantly lower motor
activity than the group treated with MK-801 alone, and would not differ significantly
from the control group or the group treated with CHPG alone. This prediction was based
on observations from rodent studies that indicated an ability of CHPG to reverse NMDAR antagonist-induced motor effects, while not having an independent effect on
spontaneous motor activity.
1.1 Subjects
Fertilized zebrafish eggs were obtained from Z-FIN Lab in Orgeon, and housed
on Bard College campus on a 14-hour lights on/off cycle. Zebrafish larvae were tested at
5 d.p.f. (days post-fertilization).
1.2 Materials
MK-801 was obtained from Research Biochemicals International (Natick, MA).
CHPG was obtained from Tocris Bioscience, Inc. CHPG sodium salt was used based on
optimal water solubility. 6.7 mg MK-801 was dissolved in 10 mL egg water to yield a
stock solution of 2000 µM MK-801; the stock was then diluted to yield 30 mL solution of
20 µM MK-801. 5 mg CHPG was dissolved in 60 mL egg water to yield a stock solution
of 360 µM CHPG, which was then diluted with egg water to yield a solution of a solution
of 180 µM CHPG. Stock solution of MK-801 and CHPG were diluted to yield a single
solution of 20 µM MK-801 and 180 µM CHPG.
Zebrafish behavior was observed using a mounted Ikegami camera over 8 well
plates on a 24 well plate dish, and recorded with Noldus EthoVisionXT at an applied
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sampling rate of 29.97 samples/second. Detection settings were set as follows: Dynamic
Subtraction; frame weight: 20; dark contrast: 19-134; subject size minimum: 8 pixels,
subject size maximum: 1519 pixels. Data output was exported into Microsoft Excel and
then transferred into SPSS. All data analyses were conducted using SPSS.
1.3

Procedure
Zebrafish were observed in round well plates each 2 cm in diameter. 8 fish were

observed at a time, with a total of 104 fish. First, 1 mL egg water was added into each
individual well. Zebrafish were transferred into each well by a pipette. Baseline activity
was recorded for 5 minutes. The egg water was removed from the wells, leaving just
enough for the larvae to swim in the perimeter. During the test period subjects received
either: a) 1 mL of egg water (control group; n = 26); b) 1 mL containing 20 µM MK-801
(n = 26); c) 1 mL containing 180 µM CHPG (n = 26); or d) 1 mL containing 20 µM MK801 and 180 µM CHPG (n = 26). We did not counter-balance the location of treatment
administration in the well plates, because based on past experience the location of
treatment administration would not be expected to affect the results. Motor activity was
recorded for 15 minutes during the test period. After testing, zebrafish were left in the
well plates for the rest of the day and observed for lethal effects of CHPG and MK-801.
1.4

Measures
Fourteen movement parameters were recorded and analyzed. These were as

follows: Total distance traveled (millimeters); duration of movement in zone B (seconds);
frequency of movement in zone B; latency to first move in zone B (seconds); duration of
movement in zone C (seconds); frequency of movement in zone C; latency to first move
in zone C (seconds); duration of movement overall (seconds); frequency of movement;
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latency to first move (seconds); duration of immobility overall (seconds); frequency of
not moving; latency to first stop moving (seconds); mean velocity (millimeters/seconds).
1.5

Data Analysis
The analysis output was exported from EthoVision as a Microsoft Excel file.

Data was analyzed in a one-way ANOVA with condition (1 = control, 2 = MK-801, 3 =
CHPG, 4 = MK-801 + CHPG) as the independent variable. A separate one-way ANOVA
was conducted to determine if baseline differences in activity existed. One-way ANOVA
tests were performed separately for each of the dependent measures described in 1.4.
Tukey post-hoc tests were performed in order to make specific group expansions. All
significance levels were set at p < 0.05.
1.6

Results
ANOVA tests conducted for all dependent variables at baseline showed that no

significant differences existed between groups prior to drug administration. Although
there was a trend for groups 3 and 4 (CHPG and MK-801/CHPG, respectively) to be less
active at baseline, there were no significant differences detected. Tables 1 and 2 display
the mean distance traveled for each group during baseline and test recordings.
Table 1. Pre-Treatment Mean Distance Traveled (5 minutes)
Condition

Control
MK801
CHPG
MK801+CHPG
Total

N

23
26
26
25
100

Mean Total
Distance Traveled
(mm)
390.9 ± 37. 7
344.2 ± 43.5
287.1 ± 38.5
290.9 ± 41. 4
326.8 ± 20.4

ANOVA Statstics

F (3, 96) = 1.422
p = .241

ASSESSMENT OF A NOVEL ANTIPSYCHOTIC IN ZEBRAFISH

41

Table 2. Post-Treatment Mean Distance Traveled (15 minutes)
Condition

N

26
26
25
25
102

Control
MK801
CHPG
MK801+CHPG
Total

Mean Total
Distance Traveled
(mm)
1232.4 ± 122.2
797.8 ± 90.0
1377.5 ± 87.5
766.1 ± 87.6
1042.9 ± 55.2

ANOVA Statistics

F (3, 98) = 9.735
p < .001

Table 1 shows that there were no pre-treatment differences in the total distance
traveled by the larvae. Table 2 shows that there was a significant difference between
groups after treatment. ANOVA tests conducted for all dependent variables at baseline
showed that no significant differences existed between groups prior to drug
administration. The results of a one-way ANOVA indicated the groups differed
significantly on total distance moved, F (3, 98) = 9.735, p < .001. Post-hoc analysis
indicated that Group 1 (control) and Group 3 (CHPG alone) were more active than Group
2 (MK-801) and Group 4 (MK-801 + CHPG). A Tukey HSD test indicated that controls
traveled a greater mean total distance than larvae treated with MK-801 (mean difference
= 434.6, p = .011) and larvae treated with MK-801/CHPG (MD = 466.3, p = .006); larvae
treated with CHPG alone traveled a greater mean distance than larvae treated with MK801 (MD = 579.6, p < .001) and larvae treated with MK-801/CHPG (MD = 611.3, p <
.001).

Total distance
traveled (mm)
(Mean±
S.E.M.)

Control

20 µM MK-801 180 µM CHPG

1232.4 ± 122.2
+^

797.8 ± 90.0
*#

1377.5 ± 87.5
+^

MK-801 +
CHPG
766.1 ± 87.6
*#

*different than controls; + different than MK-801; # different than CHPG; ^ different than MK801 and CHPG
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Experiment 1
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Figure 1. Larvae receiving MK-801 or co-administration of MK-801/CHPG traveled
significantly less than controls or larvae treated with CHPG alone (F (3, 98) = 9.735, p <
.001). Pre- and post-treatment data are shown.

This particular result was unexpected because it was hypothesized that larvae treated with
MK-801 would travel greater distance than controls, and that larvae treated with MK801/CHPG would not differ from controls. However, as is shown below, the larvae in
those both of those groups were less active than controls on several activity parameters.
Controls and larvae treated with CHPG alone entered the perimeter (zone B) of the well
more frequently than larvae treated with MK-801 or MK-801/CHPG (F (3,100) = 7.631,
p < .001), while not differing significantly from each other. A post-hoc Tukey HSD test
indicated that controls differed from larvae treated with MK-801 (MD = 60.2, p < .008)
and from larvae treated with MK-801/CHPG (MD = 65.3, p = .003). Larvae treated with
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CHPG alone entered the perimeter significantly more than larvae treated with MK-801
(MD = 59.3, p = .009) and larvae treated with MK-801/CHPG (MD = 64.3, p = .004).

Zone B
frequency

Control

MK-801

CHPG

110.1 ± 17.6
+^

49.8 ± 8.6
*#

109.1 ± 15.3
+^

MK-801 +
CHPG
44.8 ± 7.5
*#

*different than controls; + different than MK-801; # different than CHPG; ^ different than MK801 and CHPG

In addition to the result that larvae treated with MK-801 or MK-801/CHPG entered the
perimeter less frequently than controls, a one-way ANOVA indicated a significant
between groups difference on frequency of entering the center of the well that followed a
similar trend (F (3, 100) = 7.448, p < .001). Tukey post-hoc analysis indicated that
controls entered more frequently than larvae treated with MK-801 (MD = 59.96, p =
.007) and larvae treated with MK-801/CHPG (MD = 63.57, p = .004); larvae treated with
CHPG alone entered the center more frequently than larvae treated with MK-801 (MD =
57.73, p = .010) and larvae treated with MK-801/CHPG (MD = 61.34, p .006). Taken
together, these two results suggest that larvae treated with MK-801 moved less overall
than controls.

Zone C
frequency

Control

MK-801

CHPG

108.0 ± 17.6
+^

48.08 ± 8.5
*#

105.8 ± 14.7
+^

MK-801 +
CHPG
44.4 ± 7.5
*#

*different than controls; + different than MK-801; # different than CHPG; ^ different than MK801 and CHPG

This was confirmed by results indicating a significant between groups difference for
movement duration (F (3, 98) = 4.007, p = .010). A post-hoc Tukey test indicated that
larvae treated with MK-801 moved for a shorter amount of time than controls (MD = -
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134.1, p = .027) and larvae treated with CHPG alone (MD = -131.39, p = .034); the other
three groups did not differ significantly from each other.

Movement
duration (s)

Control

MK-801

CHPG

694.8 ± 28.2
+

560.7 ± 37.7
*#

692.1 ± 22.7
+

MK-801 +
CHPG
601.3 ± 42.1

*different than controls; + different than MK-801; # different than CHPG; ^ different than MK801 and CHPG

In addition to the difference in movement duration, there was significant difference
between groups for movement frequency (F (3, 100) = 6.905, p < .001), and a post-hoc
Tukey test indicated that larvae treated with MK-801 moved less frequently than larvae
treated with CHPG (MD = -71.65, p = .002), and larvae treated with CHPG alone moved
more frequently than larvae treated with MK-801/CHPG (MD = 70.6, p = .002).

Movement
frequency

Control

MK-801

CHPG

139.7 ± 15.3

89.6 ± 12.6
#

161.27 ± 13.7
+^

MK-801 +
CHPG
90.5 ± 12.7
#

*different than controls; + different than MK-801; # different than CHPG; ^ different than MK801 and CHPG

Given that the groups differed on duration of mobility, it would be expected that they
would also differ on duration of immobility. This was confirmed by results indicating
that there was a significant between groups difference for duration of time spent
immobile (F (3, 96) = 6.384, p = .001), and a post-hoc Tukey test indicated that larvae
treated with MK-801 spent less time moving than controls (MD = 133.3, p = .015) and
larvae treated with CHPG alone (MD = 157.95, p = .003); larvae treated with MK801/CHPG spent less time moving than larvae treated with CHPG alone (MD = 134, p =
.017) but did not spend significantly less time moving than controls (p = .073).
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Not moving
duration (s)

Control

MK-801

CHPG

202.3 ± 26.6
+

335.7 ± 35.5
*#

177.7 ± 14.9
+^
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MK-801 +
CHPG
311.7 ± 41.4
#

*different than controls; + different than MK-801; # different than CHPG; ^ different than MK801 and CHPG

A one-way ANOVA indicated a significant difference between groups for not moving
frequency (F (3, 100) = 6.891, p < .001), as would be expected from the results indicating
a difference between frequency of movement in each group. A post-hoc Tukey test
indicated that larvae treated with CHPG alone were more frequently immobile than
larvae treated with MK-801 (MD = 71.6, p = .002) and larvae treated with MK801/CHPG (MD = 70.5, p = .002). These results are consistent with the earlier results
indicating significant differences in movement frequency.

Not moving
frequency

Control

MK-801

CHPG

139.4 ± 15.3

89.1 ± 12.7
#

160.8 ± 13.7
+^

MK-801 +
CHPG
90.27 ± 12.7
#

*different than controls; + different than MK-801; # different than CHPG; ^ different than MK801 and CHPG

F scores for Experiment 1 are reported below in Table 3.
Table 3. F Statistics for Dependent Variables in Experiment 1
Dependent Variable
Total distance moved
Zone B duration
Zone B frequency
Zone B latency to enter
Zone C duration
Zone C frequency
Zone C latency to enter

F score
9.735
.992
7.631
1.862
2.425
7.448
.950

p value
<.001*
.400
<.001*
.141
.071
<.001*
.420
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Movement duration
Movement frequency
Latency to first move
Not moving duration
Not moving frequency
Latency to first stop moving
Mean velocity

4.007
6.905
1.479
6.384
6.891
.925
2.132
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.010*
<.001*
.225
.001*
<.001*
.432
.101

In summary, fish treated with either 20 µM MK-801 or 20µ MK-801/180 µM CHPG
tended to be more active than controls on total distance moved, frequency of entering the
perimeter of the well, frequency of entering the center of the well, movement duration,
and movement frequency, while fish treated with CHPG alone tended not to differ from
controls on any movement parameters.

Experiment 2
The results of the first experiment prompted us to modify the dosage of both MK801 and CHPG in Experiment 2. It was hypothesized that lowering the dose of MK-801
to 2 µM could effect motor behavior in the larvae that would be more consistent with
previous literature demonstrating that MK-801 can induce hyperactivity in zebrafish. It
was thought that the dose of 20 µM may have been extremely high for the larvae and thus
reduced motor activity, so a lower dose was investigated. Furthermore, because CHPG
did not appear to have an effect at the dose of 180 µM it was hypothesized that a higher
dose would be necessary in order to significantly reduce the motor effects of MK-801,
and therefore in the second experiment larvae received a dose of 360 µM CHPG. Aside
from dose levels the procedure was not modified because the data suggested that
significant differences were due to drug effects, rather than an effect of the procedure
itself.
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2.1 Procedure
In the second experiment a lower dose (2 µM) of MK-801 was used and a higher
dose (360 µM) of CHPG was used. During the test period subjects received either: a) 1
mL of egg water (control group; n = 26); b) 1 mL containing 2 µM MK-801 (n = 26); c) 1
mL containing 360 µM CHPG (n = 26); or d) 1 mL containing 2 µM MK-801 and 360
µM CHPG (n = 26). The same procedure that was used in Experiment 1 was used in
Experiment 2. The measures that were recorded were the same in both experiments.
Baseline activity was also compared across both experiments to determine if there were
differences between the subjects on the two separate days. One minor change in the
second experiment was a reduction in ambient light, which necessitated systematically
turning the lights on and off during the procedure.
2.2 Results
Baseline activity was analyzed by a one-way ANOVA and the results and
indicated no significant differences between groups prior to drug administration. Oneway ANOVA tests indicated significant differences between groups on several measures
of activity after drug administration. The results were surprising in that they indicated an
independent effect of CHPG on locomotor activity that was unexpected. In general,
larvae treated with CHPG alone were more active than larvae receiving other treatments
or controls.
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Total distance
traveled (mm)
(Mean ±
S.E.M.)

Controls

2 µM MK-801

360 µM CHPG

2371.2 ± 156.3
#

2540.4 ± 206.0

3112.6 ± 161.2
*^

48
MK-801 +
CHPG
2349.1 ± 136.3
#

*different than controls; + different than MK-801; # different than CHPG; ^ different than MK801 and CHPG

Experiment 2
3500
3000
2500
2000

Baseline
Test

1500
1000
500
0
Control
801

CHPG

MK-801 +
CHPG

Condition
Figure 2. Larvae treated with CHPG traveled significantly greater distance than controls.

Groups differed on total distance traveled (F (3, 100) = 4.562, p = .005); a Tukey posthoc test indicated that larvae treated with 360 µM CHPG traveled greater total distance
than controls (MD = 741.4, p = .012) and larvae treated with MK-801/CHPG (MD =
763.5, p = .009), but not larvae treated with 2 µM MK-801 (MD = 572.1, p = .079).
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QuickTime™ and a
decompressor
are needed to see this picture.

Figure 3. Tracks from Trial 18. From left to right, each column of two represents the different groups:
controls. MK-801, CHPG, MK-801 + CHPG. Above is the plotted tracks of movement over the 15 minute
test period, representing the total distance moved.

A one-way ANOVA indicated that groups differed significantly on duration of time spent
in zone B (F (3, 99) = 3.116, p = .030); a Tukey post-hoc test indicated that larvae treated
with 2 µM MK-801 spent more time in zone B than larvae treated with MK-801 and
CHPG (MD = 117.03, p = .046). It is not clear exactly what this result indicates.

Zone B
duration (s)

Controls

MK-801

CHPG

672.1 ± 28.4

687.7 ± 33.3
^

681.3 ± 24.9

MK-801 +
CHPG
570.7 ± 37.1

*different than controls; + different than MK-801; # different than CHPG; ^ different than MK801 and CHPG

Similarly, differences in latency to enter the center of the well seem ambiguous as to their
meaning. Analysis with a one-way ANOVA test indicated that there was a significant
between groups difference in latency to enter zone C (F (3, 99) = 3.293, p = .024); a
Tukey post-hoc test indicated that the larvae receiving MK-801/CHPG took significant
longer to enter zone C than controls (MD = 58.7, p = .044).

Zone C latency
to enter (s)

Controls

MK-801

CHPG

4.1 ± 1.4
^

5.2 ± 1.4

9.7 ± 6.0

MK-801 +
CHPG
62.8 ± 30.4
*

*different than controls; + different than MK-801; # different than CHPG; ^ different than MK801 and CHPG

ASSESSMENT OF A NOVEL ANTIPSYCHOTIC IN ZEBRAFISH

50

A one-way ANOVA test indicated significant between groups differences on movement
duration (F (3, 100) = 3.320, p = .023); a Tukey post-hoc test indicated that larvae
receiving 360 µM CHPG moved for longer than the control group (MD = 129.1, p =
.033).

Movement
duration (s)

Controls

MK-801

CHPG

586.3 ± 38.5
#

595.2 ± 40.8

715.5 ± 25.1
*

MK-801 +
CHPG
608.5 ± 23.7

*different than controls; + different than MK-801; # different than CHPG; ^ different than MK801 and CHPG

These results are consistent with the findings of a one-way ANOVA that indicated a
significant between groups difference on duration of not moving (F (3, 100) = 3.335, p
=.022); a Tukey post-hoc test indicated that the larvae treated with CHPG alone spent
significantly less time immobile than controls (MD = -129.1, p = .033), and there was a
marginally significant difference between the larvae treated with CHPG and larvae
treated with 2 µM MK-801 (MD = -120.3, p = .054).

Not moving
duration (s)

Controls

MK-801

CHPG

314.6 ± 38.4
#

305.7 ± 40.8

185.4 ± 25.1
*

MK-801 +
CHPG
292.4 ± 23.6

*different than controls; + different than MK-801; # different than CHPG; ^ different than MK801 and CHPG

Analysis by one-way ANOVA indicated a significant between groups difference on
latency to first stop moving (F (3, 100) = 4.579, p = .005); a Tukey post-hoc test
indicated that larvae treated with 2 µM MK-801 were quicker to first stop moving than
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larvae treated with MK-801/CHPG (MD = -16.4, p = .019), and larvae treated with MK801/CHPG took significantly longer to first stop moving than controls (MD = 16.7, p =
.016) and larvae treated with CHPG alone (MD = 17.04, p = .014). It is interesting to
note here that the standard error of the mean is significantly higher for the MK801/CHPG group and this could explaining the discrepancy.

Not moving
latency (s)

Controls

MK-801

CHPG

2.4 ± 0.7
^

2.7 ± 0.5
^

2.1 ± 0.4
^

MK-801 +
CHPG
19.2 ± 7.7
*+#

*different than controls; + different than MK-801; # different than CHPG; ^ different than MK801 and CHPG

Lastly, a one-way ANOVA indicated a significant between groups difference on mean
velocity (F (3, 100) = 4.059, p = .009); a post-hoc Tukey test indicated that larvae treated
with 360 µM CHPG had higher mean velocity than controls (MD = .793 mm/s, p = .015)
and larvae treated with MK-801/CHPG (MD = .756, p = .023). Taken along with the
results indicating larvae receiving CHPG moved for longer than other larvae, the higher
average velocity of these larvae is consistent with the results indicating that this group
traveled a greater total distance than controls.

Mean velocity
(mm/s)

Controls

MK-801

CHPG

2.6 ± 0.1
#

2.8 ± 0.2

3.4 ± 0.1
*^

MK-801 +
CHPG
2.7 ± 0.1
#

*different than controls; + different than MK-801; # different than CHPG; ^ different than MK801 and CHPG
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All F scores for Experiment 2 are reported below in Table 4.
Table 4. F Statistics for Dependent Variables in Experiment 2.
Dependent Variable

F Score

p Value

Total distance traveled
Zone B duration
Zone B frequency
Zone B latency to enter
Zone C duration
Zone C frequency
Zone C latency to enter
Movement duration
Movement frequency
Latency to first move
Not moving duration
Not moving frequency
Latency to first stop moving
Mean velocity

4.562
3.116
1.343
.364
2.391
1.366
3.293
3.320
.504
.301
3.335
.511
4.579
4.059

.005*
.030*
.265
.779
.073
.257
.024*
.023*
.680
.825
.022*
.676
.005*
.009*

In summary, larvae treated with CHPG alone tended to be more active than controls
(traveling greater total distance, moving for longer duration, and moving with a greater
velocity), while larvae receiving MK-801 or MK-801/CHPG generally did not exhibit
different motor behavior than controls.

Discussion
Previous research has demonstrated that adult zebrafish treated with MK-801
exhibit increased motor activity (Swain et. al. 2004; Seibt et. al. 2010; Seibt et. al. 2011),
consistent with the effects of NMDA-R antagonism in other rodent models. The findings
of Chen et. al. (2010) demonstrated that these effects are conserved in larval zebrafish.
Based on these findings, administration of MK-801 was expected to increase larval
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zebrafish motor activity in our first experiment. However, this was not observed in
Experiment 1. Rather, the zebrafish larvae treated with MK-801 or the combination of
MK-801 and CHPG showed significantly decreased motor activity compared to controls
and larvae treated with CHPG alone. Larvae treated with MK-801 traveled less total
distance than controls and larvae treated with. Furthermore, analyses of several of the
dependent variables from both experiments indicate a trend for larvae treated with MK801 and MK-801/CHPG to be less active than controls or larvae treated with CHPG
alone. The results of Experiment 1 were part of the rationale for changing the dose levels
in Experiment 2. It was considered a possibility that at the dose level of 20 µM, MK-801
was acting as an anesthetic and thereby impairing the larvae’s ability to move normally.
Indeed, very high doses of MK-801 have also been shown to impair the control of motor
movement in rats, and it is a possibility that the decreased motor activity seen in
Experiment 1 is representative of a disruption of the larvae’s ability to control their
swimming motions (Kovacic & Somanathan 2010). Therefore, we hypothesized that
administering a smaller dose of MK-801 would be more likely to elicit an increase in
motor activity that would be more consistent with the current literature.
Contrary to this hypothesis, MK-801 did not affect larval motor activity at the
dose level of 2 µM in Experiment 2. In fact, there were no significant differences
between controls and larvae treated with 2 µM MK-801, suggesting that at this dose level
MK-801 does not have an effect on motor activity in zebrafish larvae. However, it is
interesting to note that results seemed to indicate an interaction between MK-801 and
CHPG at this dose level. Larvae treated with 360 µM CHPG were more active than
controls on several parameters, but larvae who received MK-801 and CHPG co-
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administration frequently did not differ from controls on the same parameters. This
suggests that although MK-801 was not behaviorally active by itself at the 2 µM dose
level, some drug interaction between MK-801 and CHPG did prevent an overall motor
activity increase such as was seen in the larvae that received CHPG alone.
CHPG was not expected to have any effects on motor activity when administered
alone, as Kinney et al. (2003) and Chan et. al. (2008) demonstrated that CHPG does not
alter motor activity in rodents when administered alone, despite reversing motor effects
of NMDA-R antagonism in these models. While the data from Experiment 1 supports
the hypothesis that CHPG by itself will not affect motor activity, the data from
Experiment 2 indicated increased activity on several motor parameters at a dose of 360
µM. At this dose level, CHPG administration led to an increase in (1) total distance
traveled, (2) duration of movement, and (3) mean velocity, as well as a decrease in the
duration of time spent immobile, in comparison to controls. This is contrary to the
expectation that activation of mGluR5 would not affect motor behavior on its own due to
the proposed mechanisms by which mGluR5 enhances NMDA-R function. According to
Kanuma et. al. (2010) the mechanism by which activation of mGluR5 with agonist agents
enhances NMDAR function is that it is likely that activation of mGluR5 leads to PKC
phosphorylation of the ion channel associated with NMDA receptors, thereby resulting in
increased NMDA receptor sensitivity and activity, and leading to an influx of calcium
ions. However, this hypothesis comes out of findings from rodent studies, and it may not
be possible to extrapolate this proposed mechanism to a zebrafish model. In the zebrafish
brain the mGluR5 may have the ability to more directly affect glutamatergic transmission
in neuronal circuits governing motor activity, and thus CHPG-induced activity at the
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receptor leads to increased motor activity. Future research could investigate whether
administration of a high dose of another mGluR5 agonist causes the same increase in
motor activity, as well as whether inhibition of the receptor via mGluR5 agonism can
lead to a decrease in motor activity at any dose level. The findings of the present study
may suggest that in the central nervous system of the larval zebrafish mGluR5 may be
more directly linked to neuronal systems governing motor activity than in the rodent or
human nervous system. The data indicated that at 5 dpf the larval nervous system is
sufficiently developed for mGluR5 agonism to have an effect on behavior. Further
investigation into the nature of this connection could lead to a more comprehensive and
refined understanding of the glutamatergic systems in zebrafish and their relationship to
motor behavior. It should be noted that there is also always the possibility that CHPG
increased motor activity by some means other than mGluR5 agonism. The ontogeny
(development) of mGluR5 does not appear to be available in the literature regarding
mGluR5 orthologs yet. The data evidences that CHPG is behaviorally active in zebrafish
larvae at 5 d.p.f.. If the mGluR5 is not expressed by 5 dpf, it would appear that CHPG is
acting on different systems than previously thought.
With regard to potential toxicity of MK-801 and CHPG, during both experiments
well plates were kept in another room of the lab after treatment and observation, in order
for us to assess any lethal toxicity of both drugs. None of the fish died at either dose
administered. This indicates that at this dose range, lengthy exposure to either MK-801
or CHPG is not lethal to zebrafish larvae at these dose levels.
The data from experiments do not support an ability of CHPG to reverse the
effects of MK-801 at a dose of either 180 µM or 360 µM. A lack of significant
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differences between the controls and the larvae treated with MK-801/CHPG (on
dependent variables where larvae treated with MK-801 alone differed from control)
would suggest that CHPG was reversing the motor effects of CHPG. In Experiment 1, the
group receiving MK-801 and CHPG did not move for a significantly different amount of
time than the controls or the group receiving CHPG alone. However, both groups that
received MK-801 traveled for significantly less distance than the groups that did not
receive MK-801. There seems to be the possibility that in the group that received a coadministration of both drugs, CHPG was able to rescue the subjects from increased
immobility due to MK-801 administration. This tendency to spend more time immobile
than controls may indicate a disruption by NMDA-R antagonism that is reversible by
CHPG. However, it would be premature to make this conclusion in the absence of other
results supporting CHPG's ability to reverse MK-801 effects. It is likely that this effect
of CHPG on movement duration is caused via the same mechanism by which a higher
dose of CHPG increased motor activity in the second experiment. Though what exactly
this mechanism is remains for the moment unknown, the results of this study do suggest a
dose-dependent effect of CHPG on motor activity.
It should also be considered that CHPG may not be potent enough to have
reversed the effects of the high dose of MK-801 in Experiment 1 on the majority of
movement parameters. Recent literature reviews have cited lower relative potency of
some mGluR5 agonists as a rationale for the development of positive allosteric
modulators (PAMs) of mGluR5, such as the compounds CDPPB and ADX47273
(Kanuma et. al. 2010; Niswender and Conn 2010). Given that CHPG did not
demonstrate a rescue effect at a dose of 180 µM, while at a dose of 360 µM increased
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motor activity when administered alone, the data of the present study may indicate that
such a high dose of CHPG is needed to have an antipsychotic effect that there is a risk of
increased motor side effects. In the context of the development of new antipsychotics,
the implication is that positive allosteric modulation is most likely a more desirable
pharmacotherapy to investigate for the treatment of schizophrenic symptoms. Future
research could assess whether administration of an mGluR5 PAM would lead to similar
behavioral results as the dose of 360 µM CHPG.
It was hypothesized that in Experiment 1 the differences between the group
receiving MK-801/CHPG and the controls would not be statistically significant.
However, most of the differences between controls and larvae co-treated with 2 µM MK801/360 µM CHPG were indeed significant. The only non-significant differences were
(1) a Tukey post-hoc test indicated no significant difference from controls for movement
duration and movement frequency, and (2) a Tukey post-hoc test on duration and
frequency of immobility indicated no significant differences from controls. The findings
the first experiment suggested that a higher dose of CHPG was needed to reverse motor
effects of MK-801, providing the rationale for investigating the dose level of 360 µM in
Experiment 2. In the second experiment, larvae co-treated with 2 µM MK-801 and 360
µM CHPG did not differ significantly from the control group except on: (1) duration of
time in zone B, (2) latency to enter zone C, (3) latency to first stop moving. Given that
overall the larvae treated with 360 µM exhibited locomotor hyperactivity on several
measures, it would seem that the 2 µM dose of MK-801 is preventing the increases in
motor activity induced by CHPG administration, while by and large having no effect on
motor activity when administered alone.
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These results are surprising, but one plausible explanation is that the 2 µM dose of
MK-801 could have decreased activity level by such a small amount that it was not
statistically significant by itself, but was enough to prevent the motor effects that were
seen when CHPG was administered alone. One factor that could have contributed to this
effect is the fact that the drugs were administered simultaneously. It could be the case
that the simultaneous blockade of the NMDA-R by MK-801 prevented CHPG from
affecting motor behavior. CHPG has been proposed to modulate transmission at the
NMDA receptor, but if MK-801 was already preventing glutamatergic transmission it
would make sense that CHPG was unable to modulate motor activity by this proposed
mechanism. Further research could explore the mechanism by which this effect is
caused, but it would seem that currently not enough is known about metabotropic
modulation of the glutamatergic systems in the zebrafish CNS to come to a clear and
compelling conclusion for why the larvae that received co-treatment did not differ from
controls on the measures that larvae treated with CHPG did.
While the data does not largely suggest the presence of confounding variables, the
possibility should never be ignored. Importantly, it should be noted that the subjects in
the two experiments differed on several parameters of baseline activity. The subjects in
Experiment 2 tended to be more active overall than the subjects in Experiment 1. For
instance, though the movement duration of the subjects in both experiments did not differ
in a statistically significant manner, subjects in Experiment 2 moved roughly 2.5 times
greater total distance than subjects in Experiment 1. This suggests that the subjects in
Experiment 2 moved at a higher mean velocity, which is confirmed by the data (t = 3.298, df = 202, p < .001). This increased activity could be an effect of differences in
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light level between the two experiments : during the first experiment, we did not cover
the window when we began running subjects. After a few hours of testing ambient light
levels increased due to sunlight coming in the window. A majority of light was blocked
for the remaining trials. In contrast, when we ran the second experiment the window was
covered the entire time. However, because the low light level made handling the larvae
and drug administration difficult, the following procedure was followed: 1) When placing
fish in wells, lights were turned on; 2) before recording 5 minutes of baseline activity,
lights were turned off; 3) before administering the drug treatments, lights were turned on;
4) before recording 15 minutes of post-treatment activity, lights were turned off. There
has been a noted effect of light transitions on motor activity in zebrafish. Padilla et. al.
(2011) demonstrated that both level of light and and the order of light presentation can
influence motor activity in larval zebrafish 6 d.p.f.. It is unfortunate that these baseline
differences exist because they suggest possible extraneous variables affecting the data.
However, in neither experiment were there significant differences between groups during
baseline activity, suggesting that the observed drug effects can be considered valid.
Another important factor that should be mentioned is that the zebrafish larvae
used in both studies were wild-type (tupel long fin) TL zebrafish, a strain that has not
been used before in assessing the behavioral effects of MK-801 administration. Chen et.
al. (2010) reported conservation of MK-801 motor effects in zebrafish larvae, but those
were a wild-type AB strain. It may be that the TL strain is more sensitive to MK-801
treatment, and therefore the dose level of 20 µM may have had an effect that is only seen
at much higher dose levels in other strains of zebrafish. It may also be the case that there
are developmental differences in the glutamate systems between the two strains: Chen et.
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al. found that MK-801 was not behaviorally active in the AB larvae until 5 d.p.f.. It may
be that there exist subtle developmental differences at 5 d.p.f. between AB and TL larvae
which could account in part for the discrepancy between the results of Chen et. al.’s study
and the results of the present study. Additionally, it could be the case that the exposure
time (15 min) was not long enough to elicit the expected increase in motor activity in
either experiment. Because our 20 µM dose elicited a decrease in motor activity, but our
2 µM dose did not elicit any significant response, it would be interesting to conduct
further research to assess how larval TL zebrafish respond to doses in between 2-20 µM.
Lastly, there is always the possibility that having a different commercial source than that
of the research previously cited impacted MK-801 responsiveness. Further research
should investigate at what dose, if any, MK-801 can elicit increased motor activity in TL
larvae.
In summary, although the current study failed to demonstrate an increase in motor
activity following treatment with MK-801, we did demonstrate behavioral effects of a
novel mGluR5 agonist, CHPG, at a dose of 360 µM. These effects were generally
inhibited by co-administration of 2 µM MK-801. Furthermore, the results of the current
study are consistent with the findings of Padilla et. al. (2011) which indicate that light-todark transitions can influence motor activity in zebrafish larvae as early as 5 dpf. The
present data support further investigation into how the glutamate systems in the larval
zebrafish brain effect motor behavior.
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Chapter 5: Conclusion
The emergence of the glutamate hypothesis of schizophrenia represents an
important shift in focus away from dopaminergic systems and onto glutamatergic
transmission at the NMDA receptor. Dissociative anestheticsthat antagonize the NMDA
receptor, such as MK-801, have begun to be utilized as psychotomimetics due to their
ability to induce deficits that more accurately resemble the symptoms of the disorder.
Several agents that enhance NMDA-R function via activation of metabotropic glutamate
receptors have been developed and are currently being explored as alternative approaches
to antipsychotic drug therapy.
The use of animal models is an essential part of the process of understanding and
developing the pharmacological profile of novel antipsychotics. MK-801’s ability to
schizophrenic-like behavior in rodent and zebrafish models makes a full assessment of its
behavioral effects important and relevant to current progress towards improved treatment
models. The assessment of the behavioral effects of MK-801 in animal models is
relevant to the development of novel antipsychotic drugs based on the glutamate
hypothesis. The purpose of the study conducted in this senior project was to determine
whether zebrafish larvae could serve as a model to investigate the antipsychotic effects of
CHPG, a novel metabotropic glutamate receptor 5 selective agonist. The principle
questions of interest were: a) can treatment with MK-801 disrupt motor activity in
zebrafish larvae in a manner consistent with the current scientific literature?; b) what, if
any, are the motor effects induced by treatment with CHPG by itself?; and c) can coadministration of CHPG with MK-801 rescue larvae from MK-801-induced motor
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disturbances? While in the second experiment the co-administration of CHPG and MK801 did not result in any significant differences in motor activity from controls, it is
unclear by what mechanism these results is were demonstrated. The motor effects of the
highest dose of CHPG could be indicative that in the larval zebrafish mGluR5 agonism
affects behavior in a different and perhaps more direct way than in previously explored
rodent models. Furthermore, the present findings support the findings of Chen et. al.
(2010) that at a dose of 20 µM MK-801 can disrupt behavior in zebrafish larvae, but
whereas Chen et. al. found an increase in motor activity, we consistently found a decrease
in motor activity at this dose level. These findings suggest that further research ought to
be conducted regarding the character of larval zebrafish’s behavioral response to MK-801
administration. Further investigation of the mechanisms underlying the reasons that the
larvae responded the way they did to MK-801 administration could help provide a more
comprehensive model for NMDA-R mediated behavior in zebrafish. Additionally,
further research into dose-dependent responses to mGluR5 agonism could help to
illuminate how this particular receptor affects motor behavior in zebrafish.
Because this particular area of research is a growing one, easy explanations for
the results of the present study are not yet readily available in the literature. Therefore,
what this senior project seeks to contribute is several questions for possible empirical
studies in the future: Are the motor effects of 20 µM MK-801 confined to TL larvae, or
can these findings be replicated in other strains such as AB larvae? At what dose levels,
if any, will MK-801 increase spontaneous motor activity in TL larvae (5 dpf) in a way
that is consistent with the existing literature? For instance, what would be the results of
treatment with a dose of MK-801 in between the two dose levels (2 µM and 20 µM)
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administered in the present study? What would be the motor effects of longer exposure
time – for instance 30, 60, or 90 minutes? Are the motor effects of a 20 µM dose of
MK-801 different in TL larvae at 6 dpf and 7 dpf than at 5 dpf? Additionally, what are
the independent motor effects of CHPG in zebrafish larvae at doses that fall in between
the range of 180-360 µM? Can CHPG reverse MK-801-induced motor disturbances if
larvae are pre-treated with it? Does a 360 µM dose of CHPG increase motor activity in
larvae at 6 dpf or 7 dpf? Research that seeks to address these question will serve to
clarify the use of zebrafish larvae as a model of NMDA-R mediated psychosis by
providing a more sophisticated picture of how glutamate systems affect behavior in this
model.
The rising popularity of the zebrafish as a model organism for CNS disorders has
come at the same time as the developers of antipsychotic agents have shifted their focus
onto ligands that enhance glutamatergic transmission at the NMDA-R receptor. It has
been hypothesized that glutamatergic modulation presents a more comprehensive strategy
for ameliorating schizophrenic symptoms while causing less side effects than
conventionally prescribed antipsychotics. A clearer understanding of the way that
glutamate transmission effects behavior in the larval zebrafish will inform researchers as
to whether or not the larval zebrafish can be a useful model to investigate the
antipsychotic efficacy of many of these new agents. If larval zebrafish can indeed serve
as a model, it represents a cost-effective and efficient way to evaluate the efficacy of new
antipsychotics which may have far-reaching effects in combating the personal and social
costs of schizophrenia.
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